Andrew attained his Bachelor of Science in Bioengineering at Syracuse University in 2017. Throughout his undergraduate, he conducted research in regenerative medicine, tissue engineering, and stem cells—specifically working in bone tissue engineering scaffolds and methods to introduce vascularization in de novo-induced pluripotent stem cell (iPSC) derived skin tissue grafts for epidermolysis bullosa. Additionally, he worked on projects in protein nanopores and drug delivery systems for rheumatoid arthritis. He also ventured in biotech start-ups, contributing to efforts for the FDA approval of a cell-based extracorporeal liver therapy.
Andrew is currently in the final stages of his DPhil, supervised by Professor Tatjana Sauka-Spengler of the Radcliffe Department of Medicine's Weatherall Institute of Molecular Medicine and collaborates with Dr Yale Michaels at the University of British Columbia. Andrew serves as Treasurer for the Oxford Immunology Group.
He has previously worked as the Digital Innovations Project Officer at The Hill, an accelerator based at the John Radcliffe Hospital, developing a course to introduce clinicians to innovations within healthcare (e.g. machine learning) and assessing the ‘digital health’ ecosystem within Oxfordshire.
Within College, Andrew serves as the Sir Christopher Cox Junior Fellow, providing welfare support for members of New College.
Andrew's research interests lie within synthetic biology, gene therapy, and cancer immunotherapy. He investigates chimeric antigen receptor T cells (CAR-T cells); in particular, he utilises synthetic tools and genomics approaches (single cell RNA sequencing) to understand and model how CAR expression levels impact T-cell activation and response - and CAR therapy.